60 Degrees Pharmaceuticals Plans January 2027 Babesiosis Data Readout

60 Degrees Pharmaceuticals announced plans to conclude enrollment in its study of babesiosis and anticipates a data readout in January 2027. The company also intends to seek a pre-sNDA meeting with the FDA.